Journal
RHEUMATOLOGY
Volume 53, Issue 8, Pages 1369-1376Publisher
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/ket403
Keywords
systemic lupus erythematosus; type I interferon; interferon-alpha; interferon blockade; rontalizumab; sifalimumab; interferon-alpha kinoid
Categories
Funding
- Institut de Recherche Experimentale et Cliniques, Universite catholique de Louvain, Brussels, Belgium
- UCB (Chaire sur les Rhumatismes Systemiques et Inflammatoires)
Ask authors/readers for more resources
SLE is an autoimmune condition characterized by loss of tolerance to chromatin constituents and the production of ANAs. The majority of SLE patients display spontaneous expression of type I IFN-induced genes in circulating mononuclear cells and peripheral tissues, and type I IFNs play a role in the pathogenesis of the disease via the sustained activation of autoreactive T and B cells necessary for the production of pathogenic autoantibodies. Several IFN-blocking strategies are currently being evaluated in clinical trials: monoclonal antibodies directed against IFN-alpha and type I IFN-alpha receptor (IFNAR), as well as active immunization against IFN-alpha. This review describes the rationale behind these trials and the results obtained, and discusses the perspectives for further development of these drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available